Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. 2013

Myron J Levin, and Kenneth E Schmader, and John W Gnann, and Shelly A McNeil, and Timo Vesikari, and Robert F Betts, and Susan Keay, and Jon E Stek, and Nickoya D Bundick, and Shu-Chih Su, and Yanli Zhao, and Xiaoming Li, and Ivan S F Chan, and Paula W Annunziato, and Janie Parrino
University of Colorado Denver Anschutz Medical Campus, Aurora.

Prevaccination and 6-week postvaccination samples from the immunogenicity substudy (n = 2269) of the zoster vaccine (ZV) efficacy trial (N = 22 439) in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to vaccination. The varicella-zoster virus geometric mean titer (GMT) and geometric mean fold rise were higher in ZV recipients than in placebo recipients (GMT, 660.0 vs 293.1 glycoprotein enzyme-linked immunosorbent assay units/mL [P < .001], respectively; geometric mean fold rise, 2.31 vs 1.00 [P < .025]). In each group there was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster. Although these data provide strong evidence that relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined. Clinical Trials Registration. NCT00534248.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006562 Herpes Zoster An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed) Shingles,Zona,Zoster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D014645 Herpesvirus 3, Human The type species of VARICELLOVIRUS causing CHICKENPOX (varicella) and HERPES ZOSTER (shingles) in humans. Chickenpox Virus,Herpes zoster Virus,Ocular Herpes zoster Virus,VZ Virus,Varicella-Zoster Virus,HHV-3,Herpesvirus 3 (alpha), Human,Herpesvirus Varicellae,Human Herpesvirus 3,Chickenpox Viruses,Herpes zoster Viruses,VZ Viruses,Varicella Zoster Virus,Varicella-Zoster Viruses,Varicellae, Herpesvirus
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Myron J Levin, and Kenneth E Schmader, and John W Gnann, and Shelly A McNeil, and Timo Vesikari, and Robert F Betts, and Susan Keay, and Jon E Stek, and Nickoya D Bundick, and Shu-Chih Su, and Yanli Zhao, and Xiaoming Li, and Ivan S F Chan, and Paula W Annunziato, and Janie Parrino
March 2008, The Journal of infectious diseases,
Myron J Levin, and Kenneth E Schmader, and John W Gnann, and Shelly A McNeil, and Timo Vesikari, and Robert F Betts, and Susan Keay, and Jon E Stek, and Nickoya D Bundick, and Shu-Chih Su, and Yanli Zhao, and Xiaoming Li, and Ivan S F Chan, and Paula W Annunziato, and Janie Parrino
September 1975, Infection and immunity,
Myron J Levin, and Kenneth E Schmader, and John W Gnann, and Shelly A McNeil, and Timo Vesikari, and Robert F Betts, and Susan Keay, and Jon E Stek, and Nickoya D Bundick, and Shu-Chih Su, and Yanli Zhao, and Xiaoming Li, and Ivan S F Chan, and Paula W Annunziato, and Janie Parrino
September 2008, The Pediatric infectious disease journal,
Myron J Levin, and Kenneth E Schmader, and John W Gnann, and Shelly A McNeil, and Timo Vesikari, and Robert F Betts, and Susan Keay, and Jon E Stek, and Nickoya D Bundick, and Shu-Chih Su, and Yanli Zhao, and Xiaoming Li, and Ivan S F Chan, and Paula W Annunziato, and Janie Parrino
November 1985, The Journal of infectious diseases,
Myron J Levin, and Kenneth E Schmader, and John W Gnann, and Shelly A McNeil, and Timo Vesikari, and Robert F Betts, and Susan Keay, and Jon E Stek, and Nickoya D Bundick, and Shu-Chih Su, and Yanli Zhao, and Xiaoming Li, and Ivan S F Chan, and Paula W Annunziato, and Janie Parrino
May 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Myron J Levin, and Kenneth E Schmader, and John W Gnann, and Shelly A McNeil, and Timo Vesikari, and Robert F Betts, and Susan Keay, and Jon E Stek, and Nickoya D Bundick, and Shu-Chih Su, and Yanli Zhao, and Xiaoming Li, and Ivan S F Chan, and Paula W Annunziato, and Janie Parrino
May 2005, Nihon rinsho. Japanese journal of clinical medicine,
Myron J Levin, and Kenneth E Schmader, and John W Gnann, and Shelly A McNeil, and Timo Vesikari, and Robert F Betts, and Susan Keay, and Jon E Stek, and Nickoya D Bundick, and Shu-Chih Su, and Yanli Zhao, and Xiaoming Li, and Ivan S F Chan, and Paula W Annunziato, and Janie Parrino
March 1978, JAMA,
Myron J Levin, and Kenneth E Schmader, and John W Gnann, and Shelly A McNeil, and Timo Vesikari, and Robert F Betts, and Susan Keay, and Jon E Stek, and Nickoya D Bundick, and Shu-Chih Su, and Yanli Zhao, and Xiaoming Li, and Ivan S F Chan, and Paula W Annunziato, and Janie Parrino
October 1977, JAMA,
Myron J Levin, and Kenneth E Schmader, and John W Gnann, and Shelly A McNeil, and Timo Vesikari, and Robert F Betts, and Susan Keay, and Jon E Stek, and Nickoya D Bundick, and Shu-Chih Su, and Yanli Zhao, and Xiaoming Li, and Ivan S F Chan, and Paula W Annunziato, and Janie Parrino
December 1986, Biken journal,
Myron J Levin, and Kenneth E Schmader, and John W Gnann, and Shelly A McNeil, and Timo Vesikari, and Robert F Betts, and Susan Keay, and Jon E Stek, and Nickoya D Bundick, and Shu-Chih Su, and Yanli Zhao, and Xiaoming Li, and Ivan S F Chan, and Paula W Annunziato, and Janie Parrino
April 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!